CTRI/2024/02/063069Not yet recruitingPhase 4
A comparative study of fesoterodine vs mirabegron vs solifenacin in cases of overactive bladder.
VYOMA DESAI1 site in 1 country60 target enrollmentStarted: March 1, 2024Last updated:
Trial Snapshot
- Phase
- Phase 4
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Improvement in OABSS score
Study Overview
Brief Summary
Overactive bladder is associated with significant impact on quality of life because of the troublesome symptoms. Pharmacotherapy is the main stay of treatment. This study compares the three main drugs used in treatment of overactive bladder- fesoterodine, mirabegron and solifenacin
Study Design
- Study Type
- Interventional
- Allocation
- Coin toss, Lottery, toss of dice, shuffling cards etc
- Masking
- None
Eligibility Criteria
- Ages
- 18.00 Year(s) to 90.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •All cases of overactive bladder undergoing treatment at Dr. PSIMS and RF hospital.
Exclusion Criteria
- •Patients not willing to participate in the study Patients lost to follow up Patients less than 18 years of age.
Outcomes
Primary Outcomes
Improvement in OABSS score
Time Frame: 1 month
Secondary Outcomes
- Significant side effects(15 days)
Investigators
Vyoma Desai
DR PSIMS and RF, VIJAYAWADA
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Solifenacin Plus Tadalafil vs Solifenacin Alone for Overactive Bladder in FemalesOveractive BladderNCT07312955Ain Shams University80
Recruiting
Not Applicable
Early Detection of OAB and Elimination of Negative Impact on Quality of LifeNCT07371000Institute of Health Information and Statistics of the Czech Republic1,000
Not yet recruiting
Not Applicable
Effect of yogasana and kegel exercise in urinary problems of womenCTRI/2025/07/090121University Grant Commission100
Completed
Not Applicable
Effectiveness of Multimodal Therapy for Urinary Incontinence in Pediatric Spina BifidaNCT07338799Cairo University66
Completed
Phase 1
Double j Stent Related SymptomsNCT07447518Kafrelsheikh University535